Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesAmortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cellebrite DI (CLBT) Research & Development: 2020-2025

Historic Research & Development for Cellebrite DI (CLBT) over the last 5 years, with Sep 2025 value amounting to $28.1 million.

  • Cellebrite DI's Research & Development rose 8.48% to $28.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $109.6 million, marking a year-over-year increase of 15.91%. This contributed to the annual value of $98.4 million for FY2024, which is 16.62% up from last year.
  • As of Q3 2025, Cellebrite DI's Research & Development stood at $28.1 million, which was down 1.70% from $28.6 million recorded in Q2 2025.
  • Cellebrite DI's Research & Development's 5-year high stood at $28.6 million during Q2 2025, with a 5-year trough of $14.9 million in Q1 2021.
  • For the 3-year period, Cellebrite DI's Research & Development averaged around $24.3 million, with its median value being $23.7 million (2024).
  • Per our database at Business Quant, Cellebrite DI's Research & Development soared by 31.70% in 2022 and then dropped by 5.47% in 2023.
  • Quarterly analysis of 5 years shows Cellebrite DI's Research & Development stood at $18.8 million in 2021, then climbed by 4.78% to $19.7 million in 2022, then rose by 10.22% to $21.8 million in 2023, then grew by 17.69% to $25.6 million in 2024, then increased by 8.48% to $28.1 million in 2025.
  • Its Research & Development was $28.1 million in Q3 2025, compared to $28.6 million in Q2 2025 and $27.3 million in Q1 2025.